Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

Dicembre 2024

Tes Pharma Announces Extension of its Series A Financing with Indaco Venture Partners

Great news from our zoner Tes Pharma!
 

Tes Pharma, a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in oncology, renal and metabolic diseases, announced that Indaco Venture Partners has joined the Series A Financing previously led by XGEN Venture, bringing the total raise to € 15 million.
 

The financing supports the development of TES-AKI-01, the company’s candidate drug for the treatment of acute kidney injury (AKI), and the additional pipeline programs for the treatment of metabolic and oncological diseases.

AKI is a common and critical condition characterized by a sudden decline in kidney function, with as many as 100 million cases occurring worldwide annually, with no approved therapies. AKI is life-threatening, complicating up to 50% of hospital admissions who require critical care. Early intervention and effective prevention strategies are crucial to improve patient outcomes and reduce the long-term impact on kidney health. AKI and other kidney diseases have been associated with NAD+ depletion. TES-AKI-01, recovers NAD+ levels and essential cellular pathways associated with mitochondrial disfunction in kidney. TES-AKI-01 showed strong protective effect in relevant animal model of AKI.

Luca Benatti
CEO, Tes Pharma

The backing of XGEN and Indaco, specialized biotech investors, is a testament to our pioneering approach to developing first-in-class therapies for diseases with high unmet need. Coupled with our recent discoveries, this investment allows us to accelerate the development of our lead programs toward important milestones.

READ THE PRESS RELEASE
act

News

There is a lot of news to share about OpenZone. Make sure you're always up-to-date.
all the news